Biotech and health venture capital

What it is

Biotech and health venture capital is private risk capital pooled into closed-end funds and deployed into drug-development companies, medical-device makers, diagnostics firms and digital-health platforms before those businesses generate sustainable revenue. A typical fund raises capital from institutional limited partners (US pension funds, university endowments, sovereign-wealth funds and insurance companies), invests across 15-25 companies over a 10-to-12-year life and earns returns primarily through pharmaceutical acquisitions, secondarily through IPOs. Dedicated life-sciences funds (OrbiMed, RA Capital, Atlas Venture and Flagship Pioneering in the United States; Sofinnova Partners and EQT Life Sciences in Europe) operate alongside crossover funds and the corporate venture arms of large pharmaceutical groups including Pfizer, Roche and Johnson & Johnson.

History

Organized biotech VC traces to the US West Coast in the late 1970s, when investors including Kleiner Perkins backed Genentech (founded 1976 in South San Francisco), the first company to commercialize recombinant-DNA therapeutics. The closed-end limited-partnership structure that transaction popularized has governed the asset class since. Subsequent cycles tracked regulatory and scientific inflection points: the genomics wave (1998-2001), the post-crash consolidation (2002-2006), the monoclonal-antibody surge (2009-2015) and the US FDA checkpoint-inhibitor approvals from 2011 that drove an immuno-oncology boom lasting nearly a decade. The COVID-19 pandemic briefly tripled deal volumes in 2020-2021. US interest-rate rises from 2022 triggered a roughly 40-percent correction in deal value through 2023. China built a parallel ecosystem from roughly 2015, concentrating laboratories in Shanghai, Beijing and Suzhou; by 2025, Chinese labs were routinely generating clinical-stage assets licensed to US-domiciled development companies.

Current state

As of July 2026, global biotech VC has largely recovered from the 2022-2023 trough. The biobucks.co tracker logged US$17.6bn raised across 117 biotech financings globally in the first half of 2026 alone, with 35-plus rounds exceeding US$100m each. The single largest was Isomorphic Labs's US$2.1bn Series B in London, an AI-enabled drug-discovery platform spun out of DeepMind. In France, Alan's €480m Series G at a €5.5bn valuation set the record for the largest European healthtech round ever, with Dutch investor Prosus leading. In the United States, Oblenio Bio closed US$62m in June 2026 for a T-cell engager licensed from China's Leads Biolabs, typical of the China-to-US licensing model now common across the sector. The US FDA approved 46 novel drugs in 2025, 43% first-in-class, sustaining the pipeline signal that underpins investor confidence. Oncology, autoimmune conditions and AI-enabled drug-discovery platforms absorbed the largest share of 2026 commitments.

Relationships

Biotech VC sits at the intersection of three structural forces. The US FDA is the primary gatekeeper: an accelerated approval or a rejection letter can shift a fund's net asset value by hundreds of millions in a single day. Big Pharma (Pfizer, AstraZeneca, Roche, Johnson & Johnson) is the dominant buyer, with global pharmaceutical M&A exceeding US$228bn in 2025, making acquisitions the most common exit for clinical-stage biotechs. Public equity markets, principally the US Nasdaq Biotech Index, set valuation floors for IPOs and crossover rounds; a sustained window closure strands entire fund vintages. China's role has shifted from copier to originator: Chinese laboratories now license early-stage assets to Western-domiciled development companies that raise US or European venture capital, a model with growing political exposure on both sides.

What to watch

US legislative scrutiny of Chinese-originated drug assets is increasing; proposed restrictions on licensing deals with Chinese biotechs would disrupt dozens of US NewCo pipelines built on the same model as Oblenio Bio. US National Institutes of Health budget cuts by the Trump administration in 2025-2026 are thinning the academic preclinical pipeline that feeds early-stage venture investing. AI-enabled drug-discovery platforms attracted the largest individual rounds in the first half of 2026, testing whether machine-learning tools can compress the standard 10-to-12-year development timeline and shift capital away from empirical programs. European healthtech, long undersized relative to the United States, is maturing, with France's Alan at a €5.5bn valuation demonstrating that regulated insurance-plus-care platforms can sustain venture-scale returns. Whether US and London IPO windows re-open sustainably in late 2026 will determine how much of the 2022-2023 vintage finally achieves liquidity.